AKR1B10抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: A549 cells, Primary antibody: P07806(AKR1B10 Antibody) at dilution 1/184, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07806(AKR1B10 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07806(AKR1B10 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The AKR1B10 (aldo-keto reductase family 1 member B10) antibody is a key tool for studying the role of AKR1B10. an enzyme implicated in cancer metabolism and chemoresistance. AKR1B10 belongs to the aldo-keto reductase superfamily, which catalyzes the reduction of carbonyl compounds, including toxic aldehydes and ketones, into their corresponding alcohols. Initially identified as a liver-specific protein, AKR1B10 is overexpressed in several cancers, such as hepatocellular carcinoma, lung adenocarcinoma, and breast cancer, where it promotes cell proliferation, detoxification of chemotherapeutic agents (e.g., daunorubicin), and lipid metabolism regulation. Its upregulation is associated with poor prognosis and resistance to therapies.

Antibodies targeting AKR1B10 are widely used in research to detect its expression and localization in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate AKR1B10's functional roles, such as its interaction with retinoid metabolism pathways or involvement in oxidative stress responses. Monoclonal antibodies against AKR1B10 are particularly valuable for specificity in distinguishing it from homologous enzymes like AKR1B1. Additionally, AKR1B10 antibodies hold potential diagnostic value, as elevated protein levels in serum or tissues may serve as biomarkers for early cancer detection or therapeutic monitoring. Ongoing studies explore their utility in targeted therapies to inhibit AKR1B10's oncogenic activity.